Dr. Kausik Ray is a professor of public health and an esteemed cardiology consultant at the Imperial College, NHS Trust. The American diabetes association (ADA) standards of medical care in diabetes 2017 recommended considering aspirin therapy for the primary prevention of type 2 Diabetes Mellitus in patients with an increased cardiovascular risk like myocardial infarction and ischemic heart disease.
However, the introduction of the P2Y12 antagonists like ticagrelor and prasugrel, have revolutionized the management of cardiovascular disease in diabetic patients. In this exclusive commentary, Dr. Ray is shedding light on the role of antiplatelet therapy like ticagrelor for the primary prevention of cardiovascular complications in diabetic patients.
